Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Frequently asked questions
What sector does Scribe Therapeutics Inc. Common Stock (SCTX) operate in?
Scribe Therapeutics Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Scribe Therapeutics Inc. Common Stock (SCTX) current stock price?
As of the latest data, Scribe Therapeutics Inc. Common Stock stock price is $15.60, with a previous close of $15.41. Scribe Therapeutics Inc. Common Stock gained $0.20 in the last trading session, representing a 1.27% increase.
What is Scribe Therapeutics Inc. Common Stock (SCTX) current market capitalization?
Scribe Therapeutics Inc. Common Stock market cap is approximately 295.33 million.
What is Scribe Therapeutics Inc. Common Stock (SCTX) Earnings Per Share (EPS)?
The trailing EPS is -$1.84, and the forward EPS is -$3.62.
Does Scribe Therapeutics Inc. Common Stock (SCTX) pay dividends?
No. Scribe Therapeutics Inc. Common Stock does not pay a dividend.
How did Scribe Therapeutics Inc. Common Stock (SCTX) perform in its most recent earnings report?
In the last report (June 30, 2026), Scribe Therapeutics Inc. Common Stock posted an EPS surprise of 38.06% and a revenue surprise of -38.34%.
What is Scribe Therapeutics Inc. Common Stock (SCTX) beta (volatility) score?
Scribe Therapeutics Inc. Common Stock has a beta of 0.027, indicating lower volatility than the overall market.
